Clinical trials: Glaucoma, Open-Angle Glaucoma Eye
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Open-Angle Glaucoma
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach.
- Trial name
- NCT05411198
- Testing
- XEN45 (Glaucoma Gel Stent)
- Where
- 25 sites in United States, Australia
- Volunteers
- 74 people
- Sponsor
- AbbVie
Glaucoma, Ocular Hypertension
This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in Open Angle Glaucoma Eyes.
This follow-up extension study is planned to invite all patients who underwent the MINT® surgery and completed Month 24 Visit in the prior MMS EEU-7 study.
- Conditions
- Glaucoma, Ocular Hypertension, Open-Angle Glaucoma
- Trial name
- NCT07081347
- Testing
- MINT Minimally Invasive Nasal Trabeculostomy
- Where
- Armenia
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sanoculis Ltd
Ocular Hypertension, Primary Open Angle Glaucoma
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.
- Trial name
- NCT01943721
- Testing
- VISION5 Product
- Where
- Latvia
- Volunteers
- 14 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- APOLLO (NCT01749904)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone.
- Trial name
- NCT01292460
- Where
- 2 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Santen Oy
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Cataract, Glaucoma
High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP
Objective: To compare intraocular pressure lowering effect of combined sclerotomy ab interno with phacoemulsification and phacoemulsification alone, in primary or secondary open angle glaucoma patients.
- Conditions
- Cataract, Glaucoma, POAG
- Trial name
- HFDS_abinterno (NCT02312362)
- Testing
- Combined sclerotomy ab interno and phaco, Phacoemulsification with IOL implantation
- Where
- 5 sites in Egypt, Germany and 2 more
- Volunteers
- 108 people
- Sponsor
- Oertli Instrumente AG
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Open-angle Glaucoma
24 Hour IOP Lowering Efficacy of AL-3789
The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control.
- Trial name
- NCT00643669
- Testing
- AL-3789 Sterile Suspension
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01279083
- Testing
- DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
- Where
- 2 sites in United States
- Volunteers
- 147 people
- Sponsor
- Santen Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when…
- Trial name
- NCT00788541
- Testing
- Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
Minimally Invasive Nasal Trabeculostomy: Long-Term Follow-Up Extension Study
This study is a follow-up extension study conducted in continuation of the prior MINT study (MMS-EEU-4), in which the long-term (i.e., 18, 24 months) clinical outcomes of Minimally Invasive Nasal Trabeculostomy (MINT) will be…
- Trial name
- NCT06612346
- Testing
- Minimally Invasive Micro Trabeculostomy
- Where
- Armenia
- Volunteers
- 36 people
- Sponsor
- Sanoculis Ltd
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight…
- Trial name
- MAGIC (NCT05786196)
- Testing
- Ab-interno canaloplasty utilizing the iTrack Advance device, Ab-interno canaloplasty utilizing the OMNI Surgical System
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 86 people
- Sponsor
- Nova Eye, Inc.
Intraocular Pressure, Open Angle Glaucoma
A FIH Trial of the STREAMLINE™ SURGICAL SYSTEM
The purpose of this study is to evaluate the safety and Intraocular pressure lowering effectiveness of the Streamline™ Surgical System.
- Trial name
- NCT04700189
- Testing
- ab interno canaloplasty
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- New World Medical, Inc.
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Primary Open Angle Glaucoma, Open Angle Glaucoma
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open…
- Trial name
- NCT06313749
- Testing
- Minimally Invasive Micro Sclerostomy Device
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sanoculis Ltd
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open…
- Trial name
- NCT01520116
- Testing
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Altheos, Inc.